Iron Triangle Partners LP Makes New Investment in IDEAYA Biosciences, Inc. $IDYA

Iron Triangle Partners LP purchased a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 270,000 shares of the company’s stock, valued at approximately $7,347,000. IDEAYA Biosciences makes up about 1.0% of Iron Triangle Partners LP’s investment portfolio, making the stock its 24th largest holding. Iron Triangle Partners LP owned 0.31% of IDEAYA Biosciences at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Arizona State Retirement System raised its position in shares of IDEAYA Biosciences by 1.5% during the 3rd quarter. Arizona State Retirement System now owns 23,324 shares of the company’s stock worth $635,000 after purchasing an additional 353 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of IDEAYA Biosciences by 16.1% in the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after acquiring an additional 436 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of IDEAYA Biosciences by 16.1% during the third quarter. PNC Financial Services Group Inc. now owns 3,881 shares of the company’s stock valued at $106,000 after acquiring an additional 537 shares during the last quarter. E Fund Management Co. Ltd. lifted its holdings in IDEAYA Biosciences by 7.8% in the 2nd quarter. E Fund Management Co. Ltd. now owns 12,225 shares of the company’s stock valued at $257,000 after purchasing an additional 881 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its position in shares of IDEAYA Biosciences by 6.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 18,878 shares of the company’s stock valued at $397,000 after buying an additional 1,191 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IDEAYA Biosciences

In other news, Director Jeffrey Stein purchased 50,000 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were purchased at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the purchase, the director directly owned 54,281 shares of the company’s stock, valued at approximately $1,789,101.76. This represents a 1,167.95% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 2.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on IDYA shares. Guggenheim restated a “buy” rating and set a $50.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, February 18th. Wall Street Zen lowered IDEAYA Biosciences from a “buy” rating to a “sell” rating in a research note on Saturday, February 21st. UBS Group assumed coverage on IDEAYA Biosciences in a research report on Wednesday, January 7th. They set a “buy” rating and a $50.00 target price on the stock. Wedbush raised their price target on IDEAYA Biosciences from $49.00 to $52.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $49.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. Fifteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $48.69.

IDEAYA Biosciences Stock Up 0.8%

NASDAQ IDYA opened at $33.09 on Monday. IDEAYA Biosciences, Inc. has a fifty-two week low of $13.45 and a fifty-two week high of $39.28. The business has a 50 day moving average price of $33.80 and a two-hundred day moving average price of $31.56. The stock has a market cap of $2.91 billion, a PE ratio of -25.26 and a beta of 0.09.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, February 17th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.09. The firm had revenue of $21.75 million for the quarter, compared to analysts’ expectations of $5.95 million. The company’s revenue for the quarter was up 55.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.49) EPS. Sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.